249 related articles for article (PubMed ID: 32899879)
1. Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
Etienne G; Dulucq S; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Madene S; Fort MP; Bijou F; Moldovan M; Turcq B; Robbesyn F; Durrieu F; Versmée L; Katsahian S; Faberes C; Lascaux A; Mahon FX
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899879
[No Abstract] [Full Text] [Related]
2. Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G; Faberes C; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Fort MP; Bijou F; Turcq B; Robbesyn F; Durrieu F; Versmée L; Madene S; Moldovan M; Katsahian S; Charles-Nelson A; Lascaux A; Mahon FX; Dulucq S
Cancer Med; 2021 Jun; 10(11):3635-3645. PubMed ID: 33988316
[TBL] [Abstract][Full Text] [Related]
3. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
4. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
5. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
6. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Iurlo A; Cattaneo D; Consonni D; Castagnetti F; Miggiano MC; Binotto G; Bonifacio M; Rege-Cambrin G; Tiribelli M; Lunghi F; Gozzini A; Pregno P; Abruzzese E; Capodanno I; Bucelli C; Pizzuti M; Artuso S; Iezza M; Scalzulli E; La Barba G; Maggi A; Russo S; Elena C; Scortechini AR; Tafuri A; Latagliata R; Caocci G; Bocchia M; Galimberti S; Luciano L; Fava C; Foà R; Saglio G; Rosti G; Breccia M
Front Pharmacol; 2023; 14():1154377. PubMed ID: 37033642
[TBL] [Abstract][Full Text] [Related]
7. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
[No Abstract] [Full Text] [Related]
8. Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience.
Ureshino H; Kamachi K; Nishioka A; Okamoto S; Katsuya H; Yoshimura M; Kubota Y; Ando T; Kimura S
Hematol Oncol; 2021 Oct; 39(4):549-557. PubMed ID: 34117654
[TBL] [Abstract][Full Text] [Related]
9. De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China.
Luo J; Du X; Lou J; Wu J; Ma L; Huang J; Wang L; Tu C; Liu Z; Chen L; Tan Y; Luo D; Liang H; Yin C; Cao R; Zhou X; Liu Q; Liu X; Xu N
EJHaem; 2022 Nov; 3(4):1220-1230. PubMed ID: 36467815
[No Abstract] [Full Text] [Related]
10. A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia.
Martín Roldán A; Sánchez Suárez MDM; Alarcón-Payer C; Jiménez Morales A; Puerta Puerta JM
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242605
[TBL] [Abstract][Full Text] [Related]
11. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M
Expert Opin Drug Saf; 2024 Jun; ():1-11. PubMed ID: 38873693
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
14. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
Marcé S; Méndez A; Xicoy B; Estrada N; Cabezón M; Sturla AL; García MR; Angona A; Amat P; Escribano Serrat S; Scalzulli E; Morgades M; Senín A; Hernández-Boluda JC; Ferrer-Marín F; Anguita E; Cortés M; Plensa E; Breccia M; García-Gutierrez V; Zamora L;
J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337473
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
[TBL] [Abstract][Full Text] [Related]
16. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
17. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
Yu L; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
[No Abstract] [Full Text] [Related]
18. Effect of
Park H; Kim HJ; Sohn SK; Baik Y; Kim D; Lee SY; Kong JH; Kim H; Shin DY; Ahn JS; Park J; Park S; Kim I
Ther Adv Hematol; 2023; 14():20406207231205637. PubMed ID: 37929079
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of tyrosine kinase inhibitors based on
Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
[TBL] [Abstract][Full Text] [Related]
20. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
